Shima Takahiro, Minami Mariko, Tochigi Taro, Kochi Yu, Jinnouchi Fumiaki, Yamauchi Takuji, Mori Yasuo, Yoshimoto Goichi, Mizuno Shinichi, Miyamoto Toshihiro, Kato Koji, Akashi Koichi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
Center for Advanced Medical Innovation, Kyushu University Hospital, Fukuoka, Japan.
Blood Cell Ther. 2024 Apr 26;7(2):49-55. doi: 10.31547/bct-2023-033. eCollection 2024 May 25.
Infection is a major contributor to non-relapse mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Detecting infectious diseases in febrile patients during pretransplant conditioning is crucial for subsequent transplant success. Procalcitonin (PCT) is an auxiliary diagnostic marker of severe bacterial infections and has been proposed as a useful predictor of infection in patients undergoing allo-HSCT. Pre-transplant use of anti-thymocyte globulin (ATG) can cause side effects, such as fever and hypotension, which must be distinguished from infectious diseases. Although ATG administration may increase PCT levels, data on PCT levels in febrile patients after ATG administration are limited. Furthermore, no studies have compared PCT levels during allo-HSCT conditioning using ATG or non-ATG regimens. To investigate whether ATG increases PCT levels during febrile episodes in pre-transplant conditioning and whether PCT could be used to discriminate infections during this period, we analyzed 17 ATG and 59 non-ATG patients with fever and who underwent PCT level measurements during pre-transplant conditioning. Our findings revealed that ATG administration was the only significant factor that increased PCT positivity during fever ( = 0.01). In contrast, infectious diseases did not affect PCT positivity in the ATG group ( = 0.24). Furthermore, bloodstream infection was a significant risk factor for PCT positivity in patients who received non-ATG regimens ( < 0.01). Incorporating PCT levels into the diagnostic workup for infectious diseases requires careful consideration, particularly for patients receiving ATG regimens.
感染是异基因造血干细胞移植(allo-HSCT)中非复发死亡率的主要促成因素。在移植前预处理期间检测发热患者的感染性疾病对于随后的移植成功至关重要。降钙素原(PCT)是严重细菌感染的辅助诊断标志物,已被提议作为allo-HSCT患者感染的有用预测指标。移植前使用抗胸腺细胞球蛋白(ATG)可引起副作用,如发热和低血压,必须将其与感染性疾病区分开来。虽然给予ATG可能会增加PCT水平,但关于给予ATG后发热患者PCT水平的数据有限。此外,尚无研究比较使用ATG或非ATG方案进行allo-HSCT预处理期间的PCT水平。为了研究ATG在移植前预处理发热发作期间是否会增加PCT水平,以及PCT是否可用于区分此期间的感染,我们分析了17例接受ATG治疗和59例未接受ATG治疗且在移植前预处理期间进行了PCT水平测量的发热患者。我们的研究结果显示,给予ATG是发热期间增加PCT阳性率的唯一显著因素(P = 0.01)。相比之下,感染性疾病对ATG组的PCT阳性率没有影响(P = 0.24)。此外,血流感染是接受非ATG方案患者PCT阳性的显著危险因素(P < 0.01)。将PCT水平纳入感染性疾病的诊断检查需要仔细考虑,特别是对于接受ATG方案的患者。